Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Squamous Intraepithelial Lesions 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1HIV Seropositivity 1Anal Canal Carcinoma 1

Interventions

Radiotherapy 4fludarabine phosphate 2aldesleukin 2Paclitaxel 2Nivolumab 2Bevacizumab 2zimberelimab 1rocakinogene sifuplasmid 1liposomal doxorubicin 1fludarabine 1durvalumab 1dostarlimab 1belzutifan 1alovudine 1Watchful Waiting 1Vaccines, Synthetic 1VGX-3100 1Therapeutic Touch 1Specimen Handling 1Ritonavir 1Radiosurgery 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Papillomavirus Vaccines 1Observation 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1MEDI0457 1Ipilimumab 1Indinavir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vaginal Neoplasms × VGX-3100 × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡